{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T12:22:15Z","timestamp":1783513335969,"version":"3.55.0"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The incidence of intrahepatic cholangiocarcinoma (iCCA) is rising. Unfortunately, most patients present with locally advanced or metastatic disease at initial diagnosis, making them ineligible for surgical resection. Currently, the standard first-line treatment for unresectable iCCA is gemcitabine plus cisplatin combined with durvalumab or pembrolizumab, but the survival benefit remains limited. Pemigatinib is recommended as the treatment of previously treated advanced iCCA with FGFR2 fusion or rearrangement. The favorable objective response rate in FIGHT-302 study highlights its potential in salvage resection following tumor shrinkage and downstaging. Salvage resection has been implemented in various initially unresectable malignancies, significantly improving patient prognosis. To date, few reports have described salvage resection following FGFR inhibitor therapy for FGFR2 fusion-positive iCCA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      A 66-year-old female diagnosed with locally advanced iCCA harboring\n                      <jats:italic>FGFR2<\/jats:italic>\n                      fusion received 5 cycles of pemigatinib treatment after a multidisciplinary team discussion. The efficacy was assessed as partial remission per the Response Evaluation Criteria in Solid Tumors version 1.1, and the patient underwent a laparoscopic left hepatectomy guided by indocyanine green fluorescence. During the treatment, there was no evidence of severe adverse events and postoperative complications. The patient remained recurrence-free at the last follow-up of 30 months postoperatively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      This is the first report of salvage resection following first-line pemigatinib monotherapy for\n                      <jats:italic>FGFR2<\/jats:italic>\n                      fusion-positive locally advanced iCCA, with promising efficacy and acceptable safety.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1798918","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T11:54:51Z","timestamp":1783511691000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Salvage resection for FGFR2 fusion-positive intrahepatic cholangiocarcinoma after pemigatinib therapy: a case report and literature review"],"prefix":"10.3389","volume":"16","author":[{"given":"Yuhang","family":"Kang","sequence":"first","affiliation":[{"name":"Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Hepatic-Biliary-Pancreatic Surgery, the First People\u2019s Hospital of Neijiang","place":["Neijiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenru","family":"Wu","sequence":"additional","affiliation":[{"name":"Institute of Clinical Pathology, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjie","family":"Zhou","sequence":"additional","affiliation":[{"name":"Laboratory of Liver Transplantation, Key Laboratory of Transplant Engineering and Immunology, National Health Commission (NHC), West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianfu","family":"Wen","sequence":"additional","affiliation":[{"name":"Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-17-0245","article-title":"New horizons for precision medicine in biliary tract cancers","volume":"7","author":"Valle","year":"2017","journal-title":"Cancer Discov"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32803","article-title":"Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012","volume":"126","author":"Florio","year":"2020","journal-title":"Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/liv.14095","article-title":"Cholangiocarcinoma: Epidemiology and risk factors","volume":"39","author":"Khan","year":"2019","journal-title":"Liver Int"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.21037\/jgo-24-165","article-title":"Epidemiology, survival and new treatment modalities for intrahepatic cholangiocarcinoma","volume":"15","author":"Wang","year":"2024","journal-title":"J Gastrointest Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: The next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2013.5137","article-title":"Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: Systematic review and meta-analysis","volume":"149","author":"Mavros","year":"2014","journal-title":"JAMA Surg"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30289","article-title":"Intrahepatic cholangiocarcinoma: Continuing challenges and translational advances","volume":"69","author":"Sirica","year":"2019","journal-title":"Hepatology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26890","article-title":"Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma","volume":"59","author":"Arai","year":"2014","journal-title":"Hepatology"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.007","article-title":"Molecular targeted therapies: Ready for \"prime time\" in biliary tract cancer","volume":"73","author":"Lamarca","year":"2020","journal-title":"J Hepatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1146\/annurev-med-042921-024707","article-title":"Fgfr2 inhibition in cholangiocarcinoma","volume":"74","author":"Vogel","year":"2023","journal-title":"Annu Rev Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1004135","article-title":"Integrated genomic characterization reveals novel, therapeutically relevant drug targets in fgfr and egfr pathways in sporadic intrahepatic cholangiocarcinoma","volume":"10","author":"Borad","year":"2014","journal-title":"PloS Genet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.Am2015-771","article-title":"Abstract 771: Preclinical characterization of the selective fgfr inhibitor incb054828","volume":"75","author":"Liu","year":"2015","journal-title":"Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0429","article-title":"Fight-302: First-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with fgfr2 rearrangements","volume":"16","author":"Bekaii-Saab","year":"2020","journal-title":"Future Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/jco-26-00788","article-title":"Pemigatinib for unresectable or metastatic cholangiocarcinoma with fibroblast growth factor receptor-2 rearrangement: Results from the phase 3 fight-302 trial","author":"Bekaii-Saab","year":"","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","article-title":"Cholangiocarcinoma - evolving concepts and therapeutic strategies","volume":"15","author":"Ilyas","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(24)00082-2","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (Topaz-1): Patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"25","author":"Burris","year":"2024","journal-title":"Lancet Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (Keynote-966): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0042","article-title":"Biliary tract cancers, version 2.2025, nccn clinical practice guidelines in oncology","volume":"23","author":"Benson","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: Esmo clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"key":"B23","article-title":"Chemotherapy, radiotherapy, and hepatic lobectomy for hepatoblastoma in an infant: Report of a survival","volume":"68","author":"Hermann","year":"1970","journal-title":"Surgery"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-07538-x","article-title":"Neoadjuvant radiotherapy to facilitate immediate breast reconstruction: A systematic review and current clinical trials","volume":"26","author":"Singh","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31312","article-title":"Neoadjuvant treatments for locally advanced, resectable esophageal cancer: A network meta-analysis","volume":"143","author":"Chan","year":"2018","journal-title":"Int J Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-007-9549-7","article-title":"Salvage surgery following downstaging of unresectable hepatocellular carcinoma--a strategy to increase resectability","volume":"14","author":"Lau","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30600","article-title":"Total neoadjuvant therapy for rectal cancer: An emerging option","volume":"123","author":"Ludmir","year":"2017","journal-title":"Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41392-025-02498-z","article-title":"Lenvatinib plus transarterial chemoembolization and pd-1 inhibitors as conversion therapies for unresectable intermediate-advanced hepatocellular carcinoma: A phase 2 trial and exploratory biomolecular study","volume":"11","author":"Zhang","year":"2026","journal-title":"Signal Transduct Target Ther"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/s0720-048x(01)00414-4","article-title":"Arterial chemoinfusion therapy through an implanted port system for patients with unresectable intrahepatic cholangiocarcinoma--initial experience","volume":"41","author":"Tanaka","year":"2002","journal-title":"Eur J Radiol"},{"key":"B30","article-title":"Locally advanced intrahepatic cholangiocarcinoma successfully resected after transcatheter arterial chemoembolization with degradable starch microspheres: Report of a case","volume":"54","author":"Wu","year":"2007","journal-title":"Hepatogastroenterology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41392-023-01317-7","article-title":"Toripalimab combined with lenvatinib and gemox is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: A single-center, single-arm, phase 2 study","volume":"8","author":"Shi","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-11932-3","article-title":"Drug-eluting bead, irinotecan therapy of unresectable intrahepatic cholangiocarcinoma (Deltic) with concomitant systemic gemcitabine and cisplatin","volume":"29","author":"Martin","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-022-01257-z","article-title":"Combination of tace and lenvatinib as a promising option for downstaging to surgery of initially unresectable intrahepatic cholangiocarcinoma","volume":"40","author":"Yuan","year":"2022","journal-title":"Invest New Drugs"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112872","article-title":"Hepatic arterial infusion of gemox plus systemic gemcitabine chemotherapy combined with lenvatinib and pd-1 inhibitor in large unresectable intrahepatic cholangiocarcinoma","volume":"140","author":"Ni","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/1751-2980.13127","article-title":"Clinical outcomes of hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and anti-pd-1 immunotherapy for unresectable intrahepatic cholangiocarcinoma","volume":"23","author":"Zhang","year":"2022","journal-title":"J Dig Dis"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-025-18515-y","article-title":"Robotic left hepatectomy with hilar dissection and portal lymphadenectomy following preoperative gemcitabine, cisplatin, and pembrolizumab for intrahepatic cholangiocarcinoma","volume":"33","author":"Gonzalez","year":"2026","journal-title":"Ann Surg Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-025-17392-9","article-title":"Laparoscopic extended segmentectomy 8 with right hepatic vein resection after conversion therapy for advanced intrahepatic cholangiocarcinoma","volume":"32","author":"Tan","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1097\/js9.0000000000001540","article-title":"Conversion surgery intervention versus continued systemic therapy in patients with a response after pd-1\/pd-l1 inhibitor-based combination therapy for initially unresectable biliary tract cancer: A retrospective cohort study","volume":"110","author":"Wang","year":"2024","journal-title":"Int J Surg"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s00423-025-03630-x","article-title":"Survival benefit of conversion surgery for initially unresectable biliary tract cancer: A systematic review and meta-analysis","volume":"410","author":"Zhou","year":"2025","journal-title":"Langenbecks Arch Surg"},{"key":"B40","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ccell.2021.12.006","article-title":"Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma","volume":"40","author":"Dong","year":"2022","journal-title":"Cancer Cell"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103488","article-title":"An open-label study of pemigatinib in cholangiocarcinoma: Final results from fight-202","volume":"9","author":"Vogel","year":"2024","journal-title":"ESMO Open"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-024-02014-w","article-title":"Successful intrahepatic cholangiocarcinoma conversion surgery after administration of fibroblast growth factor receptor inhibitor","volume":"17","author":"Kaneko","year":"2024","journal-title":"Clin J Gastroenterol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1527372","article-title":"Systemic therapy with pemigatinib and sintilimab followed by resection for recurrent fgfr-2-positive intrahepatic cholangiocarcinoma: A case report","volume":"15","author":"Yang","year":"2025","journal-title":"Front Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajt.2024.10.023","article-title":"Neoadjuvant pemigatinib as a bridge to living donor liver transplantation for intrahepatic cholangiocarcinoma with FGFR2 gene rearrangement","volume":"25","author":"Byrne","year":"2025","journal-title":"Am J Transplant"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-16-1000","article-title":"Polyclonal secondary fgfr2 mutations drive acquired resistance to fgfr inhibition in patients with fgfr2 fusion-positive cholangiocarcinoma","volume":"7","author":"Goyal","year":"2017","journal-title":"Cancer Discov"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112139-20250310-00118","article-title":"Expert consensus on conversion therapy of biliary tract cancer (2025)","volume":"63","year":"2025","journal-title":"Zhonghua Wai Ke Za Zhi"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-04166-z","article-title":"Triple therapy in biliary tract cancers: Gemox plus immune checkpoint inhibitor in combination with lenvatinib or ngs-guided targeted therapy","volume":"149","author":"Dong","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111642","article-title":"Lenvatinib combined with pd-1 inhibitor plus gemox chemotherapy versus plus haic for advanced biliary tract cancer","volume":"129","author":"Zhang","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s00262-025-04085-1","article-title":"Efficacy and safety of local-regional therapy combined with chemotherapy, immune checkpoint inhibitors and lenvatinib as first-line treatment in advanced intrahepatic cholangiocarcinoma: A multicenter retrospective cohort study","volume":"74","author":"Li","year":"2025","journal-title":"Cancer Immunol Immunother"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1798918\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T11:54:53Z","timestamp":1783511693000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1798918\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":49,"alternative-id":["10.3389\/fonc.2026.1798918"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1798918","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"article-number":"1798918"}}